View from City Road: British Bio-tech taken on trust
Your support helps us to tell the story
From reproductive rights to climate change to Big Tech, The Independent is on the ground when the story is developing. Whether it's investigating the financials of Elon Musk's pro-Trump PAC or producing our latest documentary, 'The A Word', which shines a light on the American women fighting for reproductive rights, we know how important it is to parse out the facts from the messaging.
At such a critical moment in US history, we need reporters on the ground. Your donation allows us to keep sending journalists to speak to both sides of the story.
The Independent is trusted by Americans across the entire political spectrum. And unlike many other quality news outlets, we choose not to lock Americans out of our reporting and analysis with paywalls. We believe quality journalism should be available to everyone, paid for by those who can afford it.
Your support makes all the difference.ALONGSIDE the GPA debacle, the flop of the Telegraph issue and the disappointing price achieved by Anglian Windows, the flotation of British Bio-technology looks an unqualified success. The price of 425p which Kleinwort Benson achieved for the pounds 30m share placing was exactly in the middle of the range suggested by last month's pathfinder prospectus, and the shares quickly moved to a 25p premium when dealings began yesterday afternoon.
Only in the US did the company's plans go awry. Morgan Stanley found purchasers for fewer than a quarter of the pounds 8m shares pencilled in for US investors, affected by recent weakness of their own bio-tech sector.
British Bio-technology and its ilk are scarcely typical companies, of course. British Bio-tech comes to the market with large and growing losses, no prospect of positive cash flow for several years and a warning that it will need substantial additional financing in the future. Its value has nothing to do with the last month's stock market falls and everything to do with its chances of discovering viable treatments for Aids, cancer or asthma.
Assessing the prospects of its research lies beyond the competence of mere investment analysts. Since real breakthroughs may depend on inspiration and luck, it is not even clear that scientists are well-placed to give a meaningful view on British Bio- tech's chances. In comparison, even Eurotunnel looks a straightforward investment.
To a large extent an investment in a biotechnology company is an act of blind faith. British Bio-tech's shares are therefore only for the trusting.
Join our commenting forum
Join thought-provoking conversations, follow other Independent readers and see their replies
Comments